Cardiogen
also known as cardiac bioregulator, heart peptide
Khavinson-school cardiac-tissue bioregulator designed to support myocardial function and mitigate cardiovascular aging through peptide-mediated gene expression modulation. Animal studies demonstrate effects on cardiac homeostasis, inflammatory markers, and heat shock protein regulation. Limited PubMed indexing; Russian-tradition peptide with mechanistic data but no Phase 1+ human trials.
At a glance
SQ · Variable protocols
Primary target — Cardiovascular cell gene expression [khavinson-2022].
Pathway — Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasis [khavinson-2022].
Downstream effect — Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue.
Origin — Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology.
Feedback intact — Presumed — peptide bioregulators act via gene regulation, not receptor agonism.
| Parameter | Value |
|---|---|
| Standard dose | Variable — typically 10–20 mg per courseNo standardised human protocol; animal-derived dosing. |
| Frequency | Intermittent courses — 10–20 days, repeated periodicallyKhavinson-school bioregulators typically dosed as periodic interventions, not continuous. |
| Evidence basis | Animal models / mechanistic studiesNo Phase 1+ human trials in PubMed. |
| Route | Subcutaneous injection |
| Duration | 10–20 day courses, repeated 2–4× per yearRussian geriatric protocols; unclear extrapolation to general populations. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active malignancy (theoretical peptide growth factor concern)
- — Hypersensitivity to peptide components
- — Acute cardiac events (no safety data in acute MI, unstable angina)
- — Pregnancy / lactation (no reproductive toxicity data)
- 01Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
- 02Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
- 03Timing
Variable — often evening injection. No established circadian preference.
- 04Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
- 05Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
Sources
of 46 rendered claims carry a resolvable citation.
- [khavinson-2022]Khavinson 2022 — Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.
journal, 2022 - [kuznik-2011]Kuznik 2011 — [Heat shock proteins: aging changes, development thrombotic diseases and peptidergic regulation of genes].
journal, 2011 - [kuznik-2016]Kuznik 2016 — [The JAM Family of Molecules and Their Role in the Regulation of Physiological and Pathological Processes].
journal, 2016